Transforming growth factor-β responsiveness in DPC4/SMAD4-Null cancer cells

Molecular Carcinogenesis

Volumn 26, Issue 1, 1999, Pages 37-43

  Dai, Jia Le ^a   Schutte, Mieke ^a   Bansal, Ravi K ^a   Wilentz, Robb E ^a   Sugar, Avrahom Y ^a   Kern, Scott E ^a,b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

DPC4; Pancreatic cancer; SMAD; Transforming growth factor ; Tumor suppressor

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL CULTURE; GENE FUNCTION; GENE MUTATION; HUMAN; HUMAN CELL; PANCREAS CANCER; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ALLELES; BREAST NEOPLASMS; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; DNA-BINDING PROTEINS; GENE DELETION; GENES, TUMOR SUPPRESSOR; HUMANS; PANCREATIC NEOPLASMS; RAS PROTEINS; SIGNAL TRANSDUCTION; SMAD4 PROTEIN; TRANS-ACTIVATORS; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED;

EID: 0032828502     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(199909)26:1<37::AID-MC5>3.0.CO;2-6     Document Type: Article

References (43)

1. Hahn SA, Schutte M, Hoque ATMS, et al. DPC4, a candidate tumor-suppressor gene at 18q21.1. Science. 1996;271: 350-353.
2. Thiagalingam S, Lengauer C, Leach FS, et al. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat Genet 1996;13:343-346.
3. Schutte M, Hruban RH, Hedrick L, et al. DPC4 in various tumor types. Cancer Res 1996;56:2527-2530.
4. Zawel L, Dai JL, Buckhaults P, et al. Human Smad3 and Smad4 are sequence-specific transcription activators. Molecular Cell 1998;1:611-617.
5. Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier J. Direct binding of Smad3 and Smad4 to critical TGF-β inducible elements in the promoter of human plasminogen activator inhibitor-type I gene. EMBO J 1998;17:3091-3100.
6. Dai JL, Turnacioglu KK, Schutte M, Sugar AY, Kern SE. Dpc4 transcriptional activation and dysfunction in cancer cells. Cancer Res 1998;58:4592-4597.
7. Dai JL, Bansal RK, Kern SE. G1 cell cycle arrest and apoptosis induction by nuclear Smad4/Dpc4-Phenotypes reversed by a tumorigenic mutation. Proc Natl Acad Sci USA 1999;96: 1427-1432.
8. Sekelsky JJ, Newfeld SJ, Raftery LA, Chartoff EH, Gelbart WM. Genetic characterization and cloning of Mothers against dpp, a gene required for decapentaplegic function in Drosophila melanogaster. Genetics 1995;139: 1347-1358.
9. Savage C, Das P, Finelli AL, et al. Caenorhabditis elegans genes sma-2, sma-3, and sma-4 define a conserved family of transforming growth factor β pathway components. Proc Natl Acad Sci USA 1996;93:790-794.
10. Riggins GJ, Thiagalingam S, Rozenblum E, et al. Mad-related genes in the human. Nat Genet 1996;13:347-349.
11. Zhang Y, Feng X, We R, Derynck R. Receptor-associated Mad homologues synergize as effectors of the TGF-β response. Nature 1996;383:168-172.
12. Hoodless PA, Haerry T, Abdollah S, et al. MADR1, a MAD-related protein that functions in BMP2 signaling pathways. Cell 1996;85:489-500.
13. Eppert K, Scherer SW, Ozcelik H, et al. MADR2 maps to 18q21 and encodes a TGFβ-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 1996;86:543-552.
14. Macias-Silva M, Abdollah S, Hoodless PA, Pirone R, Attisano L, Wrana JL. MADR2 is a substrate of the TGFβ receptor and its phosphorylation is required for nuclear accumulation and signaling. Cell 1996;87:1215-1224.
15. Baker JC, Harland RM. A novel mesoderm inducer, Madr2, functions in the activin signal transduction pathway. Genes Dev 1996;10:880-889.
16. Liu X, Yue J, Frey RS, Zhu Q, Mulder KM. Transforming growth factor β signaling through Smad1 in human breast cancer cells. Cancer Res 1998;58:4752-4757.
17. Markowitz S, Wang J, Myeroff L, et al. Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science 1995;268:1336-1338.
18. Garrigue-Antar L, Munoz-Antonia T, Antonia SJ, Gesmonde J, Vellucci VF, Reiss M. Missense mutations of the transforming growth factor β type II receptor in human head and neck squamous carcinoma cells. Cancer Res 1995;55:3982-3987.
19. Park K, Kim SJ, Bang YJ, et al. Genetic changes in the transforming growth factor β (TGF-β) type II receptor gene in human gastric cancer cells: Correlation with sensitivity to growth inhibition by TGF-β. Proc Natl Acad Sci USA 1994;91:8772-8776.
20. Grady WM, Myeroff LL, Swinler SE, et al. Mutational inactivation of transforming growth factor β receptor type II in microsatellite stable colon cancers. Cancer Res 1999;59: 320-324.
21. Goggins M, Shekher M, Turnaniglu K, Yeo CJ, Hruban RH, Kern SE. Genetic alterations of the TGFβ receptor genes in pancreatic and biliary adenocarcinomas. Cancer Res 1998;58:9329-9332.
22. de Winter JP, Roelen BA, ten Dijke P, van der Burg B, van den Eijnden-van Raaij AJ. DPC4 (SMAD4) mediates transforming growth factor-β1 (TGF-β1) induced growth inhibition and transcriptional response in breast tumour cells. Oncogene 1997;14:1891-1899.
23. de Caestecker MP, Hemmati P, Larisch-Bloch S, Ajmera R, Roberts AB, Lechleider RJ. Characterization of functional domains within Smad4/DPC4. J Biol Chem 1997;272: 13690-13696.
24. Lagna G, Hata A, Hemmati-Brivanlou A, Massague J. Partnership between DPC4 and SMAD proteins in TGF-β signalling pathways. Nature 1996;383:832-836.
25. Zhang Y, Musci T, Derynck R. The tumor suppressor Smad4/ DPC4 as a central mediator of Smad function. Curr Biol 1997;7:270-276.
26. Zhou S, Buckhaults P, Zawel L, et al. Targeted deletion of Smad4 shows it is required for transforming growth factor-β and activin signaling in colorectal cancer cells. Proc Natl Acad Sci USA 1998;95:2412-2416.
27. Kleeff J, Korc M. Up-regulation of transforming growth factor (TGF)-β receptors by TGFβ1 in COLO-357 cells. J Biol Chem 1998;273:7495-7500.
28. Carcamo J, Weis FM, Ventura F, et al. Type I receptors specify growth-inhibitory and transcriptional responses to transforming growth factor β and activin. Mol Cell Biol 1994;14:3810-3821.
29. Otterson GA, Kratzke RA, Coxon A, Kim YW, Kaye FJ. Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene 1994; 9:3375-3378.
30. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992;358:80-83.
31. Morin PJ, Sparks AB, Korinek V, et al. Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science 1997;275:1787-1790.
32. Hartsough MT, Frey RS, Zipfel PA, et al. Altered transforming growth factor β signaling in epithelial cells when ras activation is blocked. J Biol Chem 1996;271:22368-22375.
33. Reimann T, Hempel U, Krautwald S, et al. Transforming growth factor-β1 induces activation of Ras, Raf-1, MEK, and MAPK in rat hepatic stellate cells. FEBS Lett 1997;403:57-60.
34. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 1995;270:27489-27494.
35. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 1995;92:7686-7689.
36. Shi YG, Wang YF, Jayaraman L, Yang HJ, Massague J, Pavletich NP. Crystal structure of a Smad MH1 domain bound to DNA: Insights on DNA binding in TGF-β signaling. Cell 1998;94:585-594.
37. Hocevar BA, Brown TL, Howe PH. TGF-β induces fibronectin synthesis through a c-Jun N-terminal kinase-dependent, Smad4-independent pathway. EMBO J 1999;18:1345-1356.
38. Mulder KM, Morris SL. Activation of p21 ras by transforming growth factor β in epithelial cells. J Biol Chem 1992;267: 5029-5031.
39. Yue J, Buard A, Mulder KM. Blockade of TGFβ3 up-regulation of p27Kip1 and p21Cip1 by expression of RasN17 in epithelial cells. Oncogene 1998;17:47-55.
40. Vojteck AB, Der CJ. Increasing complexity of the Ras signaling pathway. J Biol Chem 1998;273:19925-19928.
41. Wang W, Zhou G, Hu MCT, Yao Z, Tan TH. Activation of the hematopoietic progenitor kinase-1 (HPK1)-dependent, stress-activated c-Jun N-terminal kinase (JNK) pathway by transforming growth factor β (TGF-β)-activated kinase (TAK1), a kinase mediator of TGF β signal transduction. J Biol Chem 1997;272:22771-22775.
42. Teng DHF, Perry WL, Hogan JK, et al. Human mitogen-activated protein kinase kinase4 as a candidate tumor suppressor. Cancer Res 1997;57:4177-4182.
43. Su GH, Hilger W, Shekher MC, et al. Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene. Cancer Res 1998; 58:2339-2342.